The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer

BACKGROUND: Immune checkpoint inhibitors have aroused great expectation of tumor eradication. However, the effect of anti-PD-L1 treatment for cervical cancer is unsatisfactory and the underlying antagonist to anti-PD-L1 efficacy is remained to be studied. Here, we investigated the anti-tumor effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Fengying, Zhang, Fengying, Wang, Qian, Xu, Ying, Xu, Shuifang, Zhang, Caihong, Wang, Lihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414724/
https://www.ncbi.nlm.nih.gov/pubmed/34479503
http://dx.doi.org/10.1186/s12865-021-00451-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414724/
https://www.ncbi.nlm.nih.gov/pubmed/34479503
http://dx.doi.org/10.1186/s12865-021-00451-7

Ejemplares similares